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Human immunodeficiency virus (HIV), the causative agent of acquired 
immunodeficiency syndrome (AIDS), has infected approximately 34.0 million people 
around the world as of 2010, with 2.7 million new infections appearing yearly. That same 
year, 1.8 million people died of AIDS-related causes.1 Thus far, three key cellular 
enzymatic targets for HIV drugs have been pinpointed: reverse transcriptase, protease, 
and integrase.2 Chemical modeling using the program SYBYL 7.3 has showed that 
(S)-3-(cyclopropylethynyl)-2-methyl-2,3-dihydrobenzisothiazole 1,1-dioxide (1) has 
potential to be used as a non-nucleoside reverse transcriptase inhibitor for the treatment 
of HIV.3 
 
The proposed reaction scheme for the synthesis of 3-(cyclopropylethynyl)-2-methyl-2,3-
dihydrobenzisothiazole 1,1-dioxide (6) is shown below. 
Scheme 1 
  
A chiral preparatory column on HPLC can then be used to separate the racemic mixture. 
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The method employed by Kafri for the synthesis of the key reagent 
3-(cyclopropylethynyl)benzisothiazole 1,1-dioxide (2) gave low yields,3 and although 
modifications to this synthesis by LeCroix met with early success,4 recent trials have also 
resulted in low amounts of product formation. Given the potential of 1 for treatment of 
HIV, as well as the usefulness of this reaction scheme for analogous compounds, 
attempts to increase the yield of 2 and thereby increase the production of 1 were in order. 
Temperature, time, molar equivalents of n-butyllithium, and quenching procedures were 
systematically varied in an attempt to increase yield of intermediate 2. Additionally, mass 
spectrometry and nuclear magnetic resonance spectroscopy were used to explore 
potential side reactions and to measure the purity of the compound. 
Human Immunodeficiency Virus 
 There are two major types of HIV virus, known as HIV-1 and HIV-2. HIV-2 
infects less than 50,000 people and has manifested few mutations as of yet.5 By contrast, 
HIV-1 has four distinct lineages—that is, it was introduced into the human population 
from four separate cross-species transmission events.6 These lineages are known as 
groups M, N, O, and P.6 Group M, the most common group, can be further subdivided 
into nine clades, or mutated forms of the virus springing from a common group.5 About 
50% of all HIV infections are in the C clade of the M group.5  
 Though there is much genetic diversity among HIV viruses, several 
characteristics are present in all specimens. The HIV genome consists of two identical 
molecules of single-stranded RNA.7 All HIV genomes contain the gag gene, which 
encodes the structural components of the viral matrix and core, and the pol gene, which 
encodes enzymes used in viral replication including reverse transcriptase, integrase, and 
protease.7 In addition, every HIV virus has a membrane that contains noncovalently 
bound glycoproteins 120 and 41 (gp120 and gp41).7 Each of these traits is crucial to the 
survival of the virus. 
Although a type of white blood cell known as the T-cell is HIV’s primary target, 
the virus usually enters the body using submucosal dendritic cells.8 The virus binds to a 
C-type lectin (a protein which binds sugar at variable rates depending on the 
concentration of Ca+2)9 known as DC-SIGN  and is from there absorbed into an acidic 
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compartment within the cell, migrating with it to the lymphatic system.8 Once the virus 
has been carried to the lymphatic system, it binds to a T-cell, its primary target.8 The HIV 
virus infects T-cells through the binding of the virus’ glycoprotein 120 to the cell’s 
glycoprotein CD4. This binding induces a conformational change in the virus, exposing a 
region that then binds to the cell’s chemokine receptors, which are molecules that bind 
proteins responsible for regulating inflammatory responses. This binding in turn allows 
fusion and endocytosis to occur.5,8 
Once inside the cell, the virus uncoats and releases its reverse transcriptase 
complex using a mechanism that is not yet fully understood.10 Reverse transcriptase then 
transcribes the RNA into a double-stranded RNA/DNA hybrid.7 The RNA strand is then 
broken down, and reverse transcriptase synthesizes the complementary DNA strand to 
form a double-stranded DNA molecule.7 The reverse transciptase docks with 
microtubules and forms the preintegraton complex (PIC), which then enters the nucleus 
in a process that is also poorly understood.11 Once it is within the nucleus, the virus will 
continue its life cycle if it is successfully integrated into the host genome in a process 
mediated by the viral enzyme integrase (IN).8 The virus will then either enter a dormant 
phase and replicate along with the cell as it undergoes mitosis, immediately kill the cell, 
or use the cell’s machinery to manufacture new viruses to begin the process over again.8  
Reverse transcriptase inhibitors, as the name suggests, target reverse transcription 
as a means by which to interrupt the HIV replication cycle. Nucleoside reverse 
transcriptase inhibitors are analogous to the natural substrate of reverse transcriptase—
that is, to the DNA nucleosides.12 Like nucleosides, they are incorporated into DNA, 
allowing them to halt synthesis.12 By contrast, non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) are not necessarily analogous to natural nucleosides, and inhibit 
binding not by incorporation into the forming DNA, but by binding to a hydrophobic 
pocket on the reverse transcriptase that changes the conformation of the enzyme and 
interferes with its catalytic activity.12 Computer modeling of the hydrophobic pocket has 
indicated that (S)-3-(cyclopropylethynyl)-2-methyl-2,3-dihydrobenzisothiazole 1,1-




Lithiation proceeds through the mechanism as shown in Scheme 2 below. 
Scheme 2 
 
The reaction of the lithiated alkyne with saccharin pseudo-chloride proceeds by the 
mechanism drawn in Scheme 3 proposed by Riyam Kafri.3  
Scheme 3 
 
Reagents and Alternate Syntheses 
 Because they are strong bases, organolithium compounds will deprotonate and 
lithiate relatively acidic organic molecules.13 Lithiations are particularly favorable when 
the carbon to be deprotonated is stabilized by a conjugated π system, as with 
allylbenzene, or sp hybridization, as with ethynylcyclopropane.14 If one molar equivalent 
of an organolithium compound such as n-butyllithium is added to a terminal alkyne, the 
acetylenic carbon will be lithiated; if two equivalents are added, the propargylic carbon 
will be lithiated as well.14 If lithiation is the desired reaction, an electron-donating solvent 
such as THF should be used to stabilize the electron-starved lithium,14 
 Several relevant side-reactions are possible when organolithium compounds are 
used. Many organolithium compounds will react with simple ethers. For example, at 35 
˚C, n-butyllithium has a half-life of only 10 minutes in THF, with the two compounds 
reacting to form butane, ethylene, and the lithium enolate of acetaldehyde. The half-life 
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increases to 23.5 hours at 0 ˚C.14 Additionally n-butyllithium may add to the propargylic 
carbon as well as the terminal carbon if two molar equivalents are present.13 Care must be 
taken, therefore, to avoid the conditions under which such reactions will occur. 
There is some variation in the literature as to optimum conditions for performing 
lithiations and alkylations. Most lithiations are performed in 30–45 minutes, not 4 hours 
as suggested by Kafri.3 Gaeta et al., for instance, report a twenty minute dropwise 
addition of n-butyllithium to the alkyne followed by ten minutes of stirring at –78 ˚C.15 
Additionally, a paper by Abramovitch et. al., contains another potential workup method.16 
The reaction described between saccharin and organolithium compounds was quenched 
using ice water, and the pH was lowered to approximately pH 1 with the addition of 
dilute aqueous HCl. The aqueous layer was then separated from the organic layer using 
an ether extraction. Both of these variations were incorporated into modifications of the 
earlier synthesis. 
Procedure 
Since the presence of water is known to compromise yield, the THF was obtained 
from a dry solvent system and distilled once more using sodium with benzophenone to 
produce the diphenyl ketyl anion as an indicator. Glassware used in the reaction was 
stored in an oven and cooled in a desiccator to minimize the presence of water. Molecular 
sieves were added to the ethynylcyclopropane to ensure that it had not been contaminated 
with water, and saccharin pseudo-chloride was stored in a desiccator.  
Additionally, the n-butyllithium was titrated to standardize concentration. 
Approximately 600 mg of dry diphenylacetic acid were placed into a 25-mL Erlenmeyer 
flask and dissolved in THF. This solution was purged under nitrogen for ten minutes, and 
then titrated with n-butyllithium. The n-butyllithium preferentially removes the hydroxyl 
hydrogen. Once this reaction has gone to completion, excess n-butyllithium deprotonates 
the alpha carbon. This will turn the solution a pale-yellow color, indicating that the 




The procedure proposed by LeCroix for synthesis of the compound 
3-(cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide (2) is as follows.4 One molar 
equivalent of ethynylcyclopropane (3) in about 10 mL THF was purged under nitrogen 
for 10 to 15 minutes and cooled to –78 °C using a dry ice/acetone bath. One molar 
equivalent of 2.5 M n-butyllithium in hexanes was then added to this solution, which was 
left to stir for four hours under nitrogen while warming to between –40 °C and 0 °C. 
Meanwhile, a solution of 1.5 molar equivalents of saccharin pseudo-chloride in 
approximately 50 mL of THF was prepared, purged for 10 to 15 minutes under nitrogen, 
and cooled to –78 °C. The first solution was added dropwise to the second over the 
course of 45 minutes to 1 hour and left to stir until an hour after the beginning of the 
addition. This solution was then quenched using a saturated aqueous solution of 
ammonium chloride and allowed to warm to room temperature. The organic products 
were extracted from the aqueous layer in a separatory funnel using ether as the solvent, 
and the ether layer was dried with anhydrous magnesium sulfate. The liquid was filtered 
using a Buchner funnel and rotary evaporated, then placed on a high-vacuum line to 
remove remaining solvent. The product was purified using a column of 3:1 
ether:petroleum ether and a column of 3:1 DCM:petroleum ether. If necessary, another 
column was run using 2:1 petroleum ether:EtOAc. 
Additionally, a column of 3:1 petroleum ether:ethyl acetate was run on the raw 
product obtained using Method 18. After all of the compounds that proved mobile in that 
solvent system had eluted, methanol was added at the end to remove the rest of the 
compounds. Each spot that eluted was set aside, rotary evaporated, and weighed. Each 
sample was then analyzed through mass spectrometry using DCM as the solvent. NMR 
spectroscopy was not determined because the high-vacuum line was unavailable to 
remove solvent, and because there was insufficient time to run additional columns to 













 The variations on LeCroix’s scheme and the yields obtained are listed in Table 1 
below.  
Table 1 
Method Deviations from Procedure Molar Equiv. 
n-butyllithium 
Yield 
1 No changes to LeCroix method 1.3 22.1% 
2 No changes to LeCroix method 1.2 28.6% 
3 No changes to LeCroix method 1.1 38.0% 
4 No changes to LeCroix method 0.8 32.2% 
5 Quenched with water and 1 M HCl until pH ~1 1.2 <24.0% 
6 3.5 hour lithiation, 1.25 h addition to saccharin 
pseudo-chloride, 1 h left stirring 
0.9 <11.6% 
7 5 hour lithiation  1.0 <36.3% 
8 30 minute addition to saccharin pseudo-
chloride, 1 h left stirring  
1.3 <21.1% 
9 1 h left stirring after addition to saccharin 
pseudo-chloride 
1.2 9.8% 
10 1 h left stirring after addition to saccharin 
pseudo-chloride 
1.1 5.7% 
11 Lithiated alkyne added to saccharin pseudo-
chloride over 10 minutes 
1.2 39.3% 
12 30 minute lithiation at –78 ˚C, 1 h left stirring 
after addition to saccharin pseudo-chloride 
1.2 0% 
13 45 minute lithiation at –78 ˚C, 1 h left stirring 
after addition to saccharin pseudo-chloride  
1.2 40.4% 
14 4 hour lithiation at –78 ˚C, 1 h left stirring after 
addition to saccharin pseudo-chloride 
1.0 41.3% 
15 2 h lithiation at –78 ˚C, 10 minute addition to 
saccharin pseudo-chloride, 1 h left stirring 
1.0 <42.5% 
16 Warmed to 0 ˚C 1.0 <20.5% 
17 Warmed to 10 ˚C 1.0 <20.2% 
18 2.5 hour lithiation at –78 ˚C, 1 h addition to 
saccharin pseudo-chloride, 1 h left stirring 
1.0 <41.7% 
Note: a < indicates that the product was never completely pure even after two and 
sometimes three chromatographic columns had been run, and that the yield is based on 
the purest form the compound attained.  
 
The mass of the eluents from the column of the raw product from method 18 as well as 
their mass peaks appear in Table 2. Note that the m/z ratio will be one greater than the 
mass of the molecule. The column labeled “Approximate Millimoles” indicates the 
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approximate amounts of product in each major peak. Since presence of other peaks 
indicates that a small amount of impurities remained, these relative amounts are more 






Major Peaks Other Peaks 
1 7.0 0.03-0.06 274, 149, 111, 
177, 205, 232 
163, 113, 143, 
219, 243, 371, 
345, 305 
2 27.5 0.09 290 273, 231, 332, 
111 
3 84.6 0.28 298 268, 184, 240, 
111 
4 10.4 0.05-0.06 167, 201, 212 254, 232, 260, 
184, 111, 139, 
298, 285, 243, 
111, 139 
5 661.3 2.86 232 292, 103, 274 
6 116.6 0.44 268 184, 232, 111, 
144, 131, 199 
7 71.8 0.27–0.39 184, 268  226, 232, 103, 
111, 131, 210 
8 (methanol) 636.0 3.0-3.5 211, 183 116 
Discussion and Conclusions 
Methods 1 through 4 simply varied the relative amount of n-butyllithium added. 
This confirmed what Kafri had found in her dissertation—that although two molar 
equivalents are required to lithiate saccharin, only one molar equivalent n-butyllithium 
should be added to lithiate saccharin pseudo-chloride. Method 5 was tried because the 
paper on which Kafri’s method was based utilized this method instead of the one used by 
Kafri and LeCroix.16 Method 6 used decreased time for the lithiation step so that a 
comparison could be made with the four-hour lithiation time to test whether the longer 
time resulted in greater by-product formation. On the other hand, method 7 tested 
whether four hours was too short of a period of time for the reaction to go to completion. 
Methods 6, 8, 9, and 10 were utilized to test whether the alkylation step had enough time 
to go to completion, and methods 11 and 15 tested whether the rate of addition made a 
significant difference in reaction time as proposed by LeCroix.4 
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A clearer strategy by which to proceed presented itself when it was discovered 
that previous schemes had called for lithiation over much shorter periods of time than the 
four hours recommended by Kafri and LeCroix.15 This discovery was utilized for 
methods 12, 13, 15, and 18, in which the lithiation was conducted under shorter time 
spans. The shorter reaction times did not allow solution to warm up to anywhere near 0 
˚C, so it was unclear whether to the shorter time or the lower temperatures were 
responsible for the higher yields. For this reason, a reaction was conducted using method 
14, in which the reaction was kept at –78 ˚C for four hours, to determine whether time or 
temperature was responsible for the improvement in product formation. 
Methods 16 and 17 were utilized to determine whether the issue was one of 
kinetic vs. thermodynamic control. It was hypothesized that the contaminants observed 
were kinetic products favored at cold temperatures.  To test this, temperatures were 
increased to allow for the formation of the thermodynamic product. Yields obtained for 
these methods as compared to methods in which the lithiation was conducted at –78 ˚C 
for the duration of the reaction indicate that the desired product is obtained when the 
reaction is under kinetic control.  
Various products were observed on mass spectra. Compounds 7-10 in Figure 1 
correspond to the peaks recorded in Table 2, while compounds 11-14 correspond to peaks 
observed in other trials but not in the mass spectra corresponding of the various elutions 
obtained using method 18. 
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Figure 1 
    
    
For method 18, a rough estimate for the number of moles of each byproduct was 
determined by assuming that the major peak was the only substance present. In the case 
of multiple major peaks, a range was generated by assuming that the lowest and the 
highest molecular weight compounds were the only compounds present. This 
approximation is very loose, but gives a sense of the abundance of products relative to 
one another. 
 The most prevalent structures found were in elution 7 with peaks at 211 and 183. 
Their identity is unknown, but mass spectrometry revealed that both were present in the 
saccharin pseudo-chloride starting material. The second most prevalent was the desired 
product 2. Next came the mono-alkylated form in which the chloro group remained 
bonded to the heterocycle 7. The presence of 7 indicates either that the reaction was not 
conducted at a high enough temperature, that not enough time was allowed for the 
alkylation, or a combination of the two. 
 The next most prevalent byproducts were saccharin (8) and the bis-alkylated form 
9. The presence of the bis-alkylated form indicates either that the reaction was conducted 



































alkyne was added to the saccharin pseudo-chloride too quickly, or that there was too 
much lithiated alkyne present in relation to the saccharin pseudo-chloride. Since the 
presence of 7 indicates the exact opposite of former two possibilities, the latter two 
possibilities are more likely.  
The presence of saccharin and the unknown contaminants with m/z peaks at 211 
and 183 indicates that the amount of saccharin pseudo-chloride calculated to be present is 
incorrect. Mass spectrometry of the saccharin pseudo-chloride used indicates the 
presence of saccharin contaminants, so the origin of the saccharin observed in the mass 
spectrum of the raw product is almost certainly the saccharin pseudo-chloride starting 
material. Since the starting material is contaminated, the calculated amount of saccharin 
pseudo-chloride is likely greater than the actual amount. While saccharin does react with 
lithiated alkynes, it is less reactive than pseudo–saccharin chloride.3 The disparity 
between the calculated and actual amount of saccharin pseudo-chloride likely contributes 
to the formation of 9. 
An extremely small amount of compound 11 was formed. This indicates that there 
was a slight excess of n-butyllithium, so that it was left in solution to add to saccharin 
pseudo-chloride. It is possible, then, that the concentration used in calculating the amount 
of n-butyllithium present is slightly off, but the fact that the amount is so small indicates 
that the difference between actual and calculated amounts of n-butyllithium is not a 
significant concern.  
The rest of the compounds indicated by the mass peaks are present in vanishingly 
small amounts and are not significant contributors to yield. The peak at 177 is most likely 
a dimer of ethyl acetate, and many of the small molecular weight compounds probably 
come from the petroleum ether. 
In reactions in which 1.1 or more molar equivalents of n-butyllithium were used, 
compounds 12, 13, and 14 appeared on mass spectra. Excess n-butyllithium competed 
with ethynylcyclopropyl lithium in the alkylation reaction of saccharin pseudo-chloride. 
Thus, an excess of n-butyllithium should result in an overall reduction of yield. Although 
this trend held true for methods 1, 2, and 3, the reverse trend held true for methods 9 and 
10. This makes little sense, as it seems that additional time would allow for more addition 
of the butyl group. Regardless, the yields are quite small in methods 9 and 10.  
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Compound 15 (m/z = 212) also appeared in most mass spectra. The origin of this 
byproduct is unknown. It was thought that it might be due to a reaction of potential 
ethanol contaminants in ether with saccharin pseudo-chloride, but when saccharin 
pseudo-chloride was placed in a vial of diethyl ether, compound 15 was not observed in 
the mass spectrum. 
There is no indication that the n-butyllithium and THF underwent degradation of 
the kind described in the introduction. If the acetaldehyde enolate were forming, it would 
be expected to compete with ethynylcyclopropyl lithium in the reaction, and one or both 
of the compounds in Figure 2 would be present. Since the half-life of n-butyllithium even 
at temperatures as high as 0 ˚C is 23.5 h,17 it is unlikely that n-butyllithium decayed 
enough for this to occur in significant amounts using any of the methods described here, 




One potential means by which to speed up the lithiation step that was not explored 
here is the use of tert-butyllithium instead of n-butyllithium. Carbon-lithium bonds tend 
to have a strong covalent character, which in turn leads to their complexation in solution. 
Less branched organolithium reagents, such as n-butyllithium, tend to former stronger 
complexes than more branched organolithium reagents, such as tert-butyllithium. 
Because these complexes are stronger, the time to lithiate is longer. However, it is 
possible that the use of tert-butyllithium would decrease yield, since this complexation 
increases the bond polarity between lithium and carbon, which in turn lowers the 
activation energy for lithiation reactions. Additionally, although both n-butyllithium and 
tert-butyllithium are violently reactive with the moisture in the air, tert-butyllithium is 














tert-butyllithium degrades more quickly than does n-butyllithium, with a half-life of a 
little over five and a half hours in THF even as cold as –40 ˚C.17 
The most likely source of procedural error for this reaction stems from the fact 
that it must be performed under completely dry conditions. Although the reactions were 
conducted under nitrogen in septum-sealed flasks, it was still difficult to keep every bit of 
moisture from the atmosphere out of the reaction. Since water reacts with n-butyllithium, 
the presence of moisture would be problematic.  
Another limitation to this study involves the number of molar equivalents of 
n-butyllithium. Because it was initially thought that the n-butyllithium sent by the 
company was 2.5 M, many of the trials were conducted with more or less than one 
equivalent of n-butyllithium. Thus, an additional variable was inadvertently introduced 
for several of the trials. It is thus more difficult to draw direct correlation with any one 
variable. 
The temperature at which the lithiation takes place appears to be the most 
important factor in obtaining a higher yield. For the methods in which the temperature 
was kept around –78 ˚C for the duration of the reaction, yields remained above 40%; for 
those in which the reaction was allowed to warm to above –40 ˚C, on the other hand, the 
maximum yield obtained was 39%. Synthesis of 3-(cyclopropylethynyl)benzisothiazole 
1,1-dioxide should be conducted over two to four hours and should be kept near -78 ˚C 
for the duration of the reaction. In addition, the lithiated alkyne should be added slowly to 
the saccharin pseudo-chloride over the course of 45 minutes or more, as rapid addition 
seems to have a more deleterious effect on yield than the heating of the lithiated alkyne 
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